Zoetis Inc. $ZTS Shares Sold by Stokes Capital Advisors LLC

Stokes Capital Advisors LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 64.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,624 shares of the company’s stock after selling 15,506 shares during the quarter. Stokes Capital Advisors LLC’s holdings in Zoetis were worth $1,085,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC lifted its stake in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth about $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis in the third quarter valued at about $31,000. Holos Integrated Wealth LLC purchased a new position in Zoetis in the fourth quarter valued at about $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ZTS shares. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Piper Sandler restated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

Zoetis stock opened at $116.65 on Thursday. The stock has a market capitalization of $49.24 billion, a P/E ratio of 19.38, a P/E/G ratio of 1.77 and a beta of 0.95. Zoetis Inc. has a 12-month low of $113.30 and a 12-month high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm’s 50-day moving average is $123.79 and its two-hundred day moving average is $129.67.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.